PVR and cancer: Clinically, NOTCH3 mutation or low expression independently predicted improved survival in immunotherapy-treated CRC and pan-cancer cohorts.<h4>Conclusion</h4>NOTCH3 is a pivotal regulator of immune evasion in CRC via the RBPJ-PVR axis.